Savara Inc.
NASDAQ:SVRA
2.72 (USD) • At close January 14, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Savara Inc. |
Symbool | SVRA |
Munteenheid | USD |
Prijs | 2.72 |
Beurswaarde | 466,803,680 |
Dividendpercentage | 0% |
52-weken bereik | 2.6 - 5.7 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Matthew Pauls J.D., M.B.A. |
Website | https://www.savarapharma.com |
An error occurred while fetching data.
Over Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)